Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 25.551 mg/ml (equivalent: escitalopram, qty 20 mg/ml) - oral liquid, solution - excipient ingredients: sodium hydroxide; ethanol; purified water; propyl gallate; citric acid - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - escitalopram oxalate - oral drops solution - 20 mg/ml

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - escitalopram - oral drops solution - 10 micromol

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; purified water; macrogol 400 - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - escitalopram oxalate, quantity: 12.77 mg (equivalent: escitalopram, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; purified talc; titanium dioxide; hypromellose; purified water; macrogol 400 - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - escitalopram - oral drops solution - 10

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

allergan, inc. - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram 5 mg - lexapro is indicated for the treatment of: • major depressive disorder (mdd) in adults and pediatric patients 12 years of age and older. • generalized anxiety disorder (gad) in adults and pediatric patients 7 years of age and older. lexapro is contraindicated in patients: - taking maois with lexapro or within 14 days of stopping treatment with lexapro because of an increased risk of serotonin syndrome. the use of lexapro within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration ( 2.7 ) and warnings and precautions ( 5.2 )] . starting lexapro in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration ( 2.6 ) and  warnings and precautions ( 5.2 ) ]. - taking pimozide [see drug interactions ( 7 ) ] .   - with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in lexapro.

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

menarini international operations luxembourg s.a. - dexketoprofen trometamol - solution for injection/infusion - 50 mg/2ml - propionic acid derivatives; dexketoprofen

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - escitalopram - orodispersible tablet - 20 milligram

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

h. lundbeck a/s - escitalopram - orodispersible tablet - 10 milligram